Research
Hormonal
Carriers of the ADRB2 Gln27Glu polymorphism experience increased obesity risk when consuming high carbohydrate diets (>49% total energy), whereas non-carriers do not show this specific dietary interaction.
If you carry the ADRB2 Glu27 variant, limiting carbohydrates to less than 49% of your total daily energy intake may help reduce obesity risk. Standard high-carb diets might disproportionately increase your risk compared to non-carriers.
GoodConditionalHIGH confidence
This finding suggests that a dietary intake higher than the median CHO consumption (>49% total energy) produces an increased obesity risk in those women carrying the Glu27 allele (OR 2.56, P=0.051) when adjusted for age and physical activity.
Why this rating
Based on case-control studies with adjusted odds ratios and statistical significance, though observational in nature.
Source
Interaction between genes and lifestyle factors on obesity
Amelia Martí et al. · Proceedings of The Nutrition Society · 2008
DOI 10.1017/s002966510800596x
narrative_reviewCited 196×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- Carriers of the ADRB3 Trp64Arg polymorphism have a significantly higher risk of obesity when engaging in low levels of physical activity, but this risk is not apparent in active subjects.Good
- Carriers of the ADRB2 Gln27Glu polymorphism, particularly females, face a significantly higher obesity risk associated with sedentary behavior (high TV watching time), and may not benefit from reducing sedentary time as much as non-carriers.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →